Glycoconjugate vaccines. What next?
The principle that infants can be protected from invasive diseases caused by encapsulated organisms has been proved with the introduction of Haemophilus influenzae type b conjugate vaccines. The use of glycoconjugates to implement some of the goals of the Children's Vaccine Initiative requires a clear delineation of the chemical and immunological specifications for optimal vaccines.
Stein
K E
KE
D017951:Antigen Presentation / Q000276:immunology*; D015195:Drug Design; D006001:Glycoconjugates / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D008956:Models, Chemical; D009844:Oligosaccharides / Q000737:chemistry / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D018074:Vaccines, Conjugate / Q000276:immunology*
D006001:Glycoconjugates; D009844:Oligosaccharides; D018074:Vaccines, Conjugate